N
GILD icon

Natixis’s Gilead Sciences GILD Stock Holding History

Natixis’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$1.72M – 1064
2022
Q4 		$1.72M Hold
20,000
– – 0.01% 558
2022
Q3 		$1.25M Sell
20,000
-23,913
-54% -$1.51M 0.01% 712
2022
Q2 		$2.72M Buy
+43,913
New +$2.72M 0.01% 592

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Natixis's GILD Position: Q1 2026 in Review

Natixis reduced its Gilead Sciences (GILD) stake by 75% in Q1 2026, selling an estimated $66.3M and leaving 156,715 shares worth $21.8M. The position accounts for 0.08% of the portfolio, ranked #178.

Natixis first reported a position in GILD in Q3 2015 and has held it in 42 quarters since. The position peaked at $218M in Q3 2018. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Natixis held 156,715 shares of Gilead Sciences worth $21.8M as of Q1 2026.
  • Natixis sold 473,116 Gilead Sciences shares in Q1 2026, an estimated $66.3M.
  • Gilead Sciences made up 0.08% of Natixis's portfolio in Q1 2026, its #178 holding.
  • Natixis first reported a position in Gilead Sciences in Q3 2015 and has held it in 42 quarters since.
  • Natixis's Gilead Sciences position peaked at $218M in Q3 2018.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.